- $1.02bn
- $763.62m
- $333.79m
- 86
- 43
- 69
- 73
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.79 | ||
| PEG Ratio (f) | 0.28 | ||
| EPS Growth (f) | 771.8% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.71 | ||
| Price to Tang. Book | 3.42 | ||
| Price to Free Cashflow | 32.45 | ||
| Price to Sales | 3.07 | ||
| EV to EBITDA | 13.89 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.15% | ||
| Return on Equity | 16.43% | ||
| Operating Margin | 12.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 192.19 | 296.4 | 321.79 | 280.32 | 333.79 | 370.7 | 426.78 | 21.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +72.44 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
Directors
- Michael Goldberg NEC (63)
- Reginald Seeto PRE (49)
- Ankur Dhingra CFO (45)
- Sasha King CMO (35)
- Marcel Konrad VPR (45)
- Alexander Johnson OTH (47)
- Peter Maag DRC (54)
- Arthur Torres DRC (74)
- Hannah Valantine DRC
- George Bickerstaff IND (65)
- Frederick Cohen IND (64)
- Grace Colon IND (54)
- Christine Cournoyer IND (69)
- William Hagstrom IND (63)
- Ralph Snyderman IND (81)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 21st, 1998
- Public Since
- July 17th, 2014
- No. of Shareholders
- 59
- No. of Employees
- 644
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 55,425,899
- Address
- 8000 Marina Blvd, 4Th Floor, BRISBANE, 94005
- Web
- https://www.caredx.com/
- Phone
- +1 4152872300
- Contact
- Greg Chodaczek
- Auditors
- Deloitte & Touche LLP
Upcoming Events for CDNA
Q1 2025 CareDx Inc Earnings Call
CareDx Inc Annual Shareholders Meeting
Q2 2025 CareDx Inc Earnings Release
Similar to CDNA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the CareDx share price?
As of Today at 19:47 UTC, shares in CareDx are trading at $18.48. This share price information is delayed by 15 minutes.
How has the CareDx share price performed this year?
Shares in CareDx last closed at $18.48 and the price had moved by +144.44% over the past 365 days. In terms of relative price strength the CareDx share price has outperformed the S&P500 Index by +125.63% over the past year.
What are the analyst and broker recommendations for CareDx?
The overall consensus recommendation for CareDx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CareDx dividend yield?
CareDx does not currently pay a dividend.
Does CareDx pay a dividend?
CareDx does not currently pay a dividend.
When does CareDx next pay dividends?
CareDx does not currently pay a dividend.
How do I buy CareDx shares?
To buy shares in CareDx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CareDx?
As of the previous close price of $18.48, shares in CareDx had a market capitalisation of $1.02bn.
Where are CareDx shares listed?
Here are the trading details for CareDx:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CDNA
What kind of share is CareDx?
Based on an overall assessment of its quality, value and momentum CareDx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CareDx share price forecast for 2025?
The analyst consensus target price for shares in CareDx is $31.06. That is 68.07% above the last closing price of $18.48.
Analysts covering CareDx currently have a consensus Earnings Per Share (EPS) forecast of $0.61 for the next financial year.
Find out moreWhat is the trend in the CareDx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CareDx. Over the past six months, its share price has underperformed the S&P500 Index by -13.01%.
As of the last closing price of $18.48, shares in CareDx were trading -20.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CareDx PE Ratio?
The CareDx PE ratio based on its reported earnings over the past 12 months is 24.79. The shares last closed at $18.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CareDx?
CareDx's management team is headed by:
- Michael Goldberg - NEC
- Reginald Seeto - PRE
- Ankur Dhingra - CFO
- Sasha King - CMO
- Marcel Konrad - VPR
- Alexander Johnson - OTH
- Peter Maag - DRC
- Arthur Torres - DRC
- Hannah Valantine - DRC
- George Bickerstaff - IND
- Frederick Cohen - IND
- Grace Colon - IND
- Christine Cournoyer - IND
- William Hagstrom - IND
- Ralph Snyderman - IND